Related references
Note: Only part of the references are listed.Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
Melanie Drolet et al.
LANCET INFECTIOUS DISEASES (2015)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
E. A. Joura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial
Matti Lehtinen et al.
VACCINE (2015)
Evaluation of Human Papillomavirus Type Replacement Postvaccination Must Account for Diagnostic Artifacts: Masking of HPV52 by HPV16 in Anogenital Specimens
Joseph E. Tota et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2015)
Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination
Joseph E. Tota et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2013)
Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
Anne Szarewski et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England
D. Mesher et al.
VACCINE (2013)
Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination
Johanna Palmroth et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler et al.
LANCET ONCOLOGY (2012)
Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction
Jessica A. Kahn et al.
PEDIATRICS (2012)
Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
Beatriz Serrano et al.
INFECTIOUS AGENTS AND CANCER (2012)
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication
Ni Li et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Serotype replacement in disease after pneumococcal vaccination
Daniel M. Weinberger et al.
LANCET (2011)
Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies
Joseph E. Tota et al.
PREVENTIVE MEDICINE (2011)
Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
Rolando Herrero et al.
CANCER DISCOVERY (2011)
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Silvia de Sanjose et al.
LANCET ONCOLOGY (2010)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
Cosette M. Wheeler et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
Darron R. Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline
Mark Schiffman et al.
Infectious Agents and Cancer (2009)
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
Francis J. Dessy et al.
HUMAN VACCINES (2008)
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica
Rolando Herrero et al.
VACCINE (2008)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR
Leen-Jan van Doorn et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Against which human papillomavirus types shall we vaccinate and screen?: The international perspective
N Muñoz et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Share Paper
